Exelixis (EXEL) Other financing activities (2010 - 2026)
Exelixis (EXEL) posted quarterly Other financing activities of $7.5 million for Q2 2026, down 35.74% year-over-year from $11.6 million in Q2 2025, and down 5.12% quarter-over-quarter from $7.9 million in Q1 2026.
Analysis
Exelixis (EXEL) Other financing activities (2010 - 2026) Analysis & Trends
Exelixis' Other financing activities history runs 17 years deep, the most recent figure standing at $7.5 million for Q2 2026.
- In Q2 2026, Other financing activities fell 35.74% year-over-year to $7.5 million; the TTM figure through Apr 2026 stood at $45.0 million (down 30.97% YoY), while the FY2026 annual figure was $49.1 million, down 20.55% from the prior year.
- Other financing activities for Q2 2026 stood at $7.5 million, down from $7.9 million in the prior quarter.
- The five-year high for Other financing activities was $26.1 million in Q3 2025, with the low at $2.9 million in Q3 2022.
- The 5-year median for Other financing activities is $8.3 million (2024), against an average of $10.3 million.
- The sharpest annual moves came in 2024 and 2025: Other financing activities jumped 186.09% in 2024, then slumped 82.05% in 2025.
- Exelixis' Other financing activities stood at $5.2 million in 2022, then surged by 74.97% to $9.1 million in 2023, then surged by 117.25% to $19.8 million in 2024, then plunged by 82.05% to $3.6 million in 2025, then surged by 110.36% to $7.5 million in 2026.
- Business Quant data shows EXEL's Other financing activities at $7.5 million in Q2 2026, $7.9 million in Q1 2026, and $3.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 15.44 Mn |
| Apr 3, 2026 | 7.47 Mn |
| Jan 2, 2026 | 7.88 Mn |
| Oct 3, 2025 | 3.55 Mn |
| Jul 4, 2025 | 26.08 Mn |
| Apr 4, 2025 | 11.63 Mn |
| Jan 3, 2025 | 18.82 Mn |
| Sep 27, 2024 | 19.79 Mn |
| Jun 28, 2024 | 14.92 Mn |
| Mar 29, 2024 | 8.32 Mn |
| Dec 29, 2023 | 9.11 Mn |
| Sep 29, 2023 | 6.92 Mn |
| Jun 30, 2023 | 10.28 Mn |
| Mar 31, 2023 | 7.14 Mn |
| Dec 30, 2022 | 5.21 Mn |
| Sep 30, 2022 | 2.89 Mn |
| Jul 1, 2022 | 10.90 Mn |
| Apr 1, 2022 | 4.89 Mn |
| Dec 31, 2021 | 6.07 Mn |
| Oct 1, 2021 | 2.76 Mn |